Carbamazepine
NDC Package 29033-019-12

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Carbamazepine is used to prevent and control seizures. Marketed by Nostrum Laboratories, Inc., this product is identified by NDC 29033-019 and is authorized under FDA application ANDA076697.

Identification & Billing

NDC Package Code
29033-019-12
Package Description
120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
29033001912
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
120 EA
RxNorm Crosswalk
  • RxCUI: 200131 - carBAMazepine 300 MG 12HR Extended Release Oral Capsule
  • RxCUI: 200131 - 12 HR carbamazepine 300 MG Extended Release Oral Capsule
  • RxCUI: 200131 - carbamazepine 300 MG 12 HR Extended Release Oral Capsule
  • RxCUI: 200133 - carBAMazepine 200 MG 12HR Extended Release Oral Capsule
  • RxCUI: 200133 - 12 HR carbamazepine 200 MG Extended Release Oral Capsule

Clinical Specifications

Proprietary Name
Carbamazepine
Dosage Form
-
Usage Information
Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.

Regulatory & Marketing

Labeler Name
Nostrum Laboratories, Inc.
FDA Application #
ANDA076697
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-17-2020
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 29033-019-12 identifies a specific commercial package of 120 capsule, extended release in 1 bottle of Carbamazepine, labeled by Nostrum Laboratories, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Nostrum Laboratories, Inc. on February 17, 2020. The current certification is valid through December 31, 2025.

What are the primary indications for this medication?

Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.

How is this Nostrum Laboratories, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 29033001912. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
29033-019-12
11-Digit CMS (5-4-2)
29033-0019-12

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.